578 related articles for article (PubMed ID: 22440946)
1. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials.
Rothwell PM; Price JF; Fowkes FG; Zanchetti A; Roncaglioni MC; Tognoni G; Lee R; Belch JF; Wilson M; Mehta Z; Meade TW
Lancet; 2012 Apr; 379(9826):1602-12. PubMed ID: 22440946
[TBL] [Abstract][Full Text] [Related]
2. Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials.
Rothwell PM; Wilson M; Price JF; Belch JF; Meade TW; Mehta Z
Lancet; 2012 Apr; 379(9826):1591-601. PubMed ID: 22440947
[TBL] [Abstract][Full Text] [Related]
3. Aspirin for prophylactic use in the primary prevention of cardiovascular disease and cancer: a systematic review and overview of reviews.
Sutcliffe P; Connock M; Gurung T; Freeman K; Johnson S; Kandala NB; Grove A; Gurung B; Morrow S; Clarke A
Health Technol Assess; 2013 Sep; 17(43):1-253. PubMed ID: 24074752
[TBL] [Abstract][Full Text] [Related]
4. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.
; Baigent C; Blackwell L; Collins R; Emberson J; Godwin J; Peto R; Buring J; Hennekens C; Kearney P; Meade T; Patrono C; Roncaglioni MC; Zanchetti A
Lancet; 2009 May; 373(9678):1849-60. PubMed ID: 19482214
[TBL] [Abstract][Full Text] [Related]
5. Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials.
Algra AM; Rothwell PM
Lancet Oncol; 2012 May; 13(5):518-27. PubMed ID: 22440112
[TBL] [Abstract][Full Text] [Related]
6. Effects of aspirin on risks of vascular events and cancer according to bodyweight and dose: analysis of individual patient data from randomised trials.
Rothwell PM; Cook NR; Gaziano JM; Price JF; Belch JFF; Roncaglioni MC; Morimoto T; Mehta Z
Lancet; 2018 Aug; 392(10145):387-399. PubMed ID: 30017552
[TBL] [Abstract][Full Text] [Related]
7. Age-specific risks, severity, time course, and outcome of bleeding on long-term antiplatelet treatment after vascular events: a population-based cohort study.
Li L; Geraghty OC; Mehta Z; Rothwell PM;
Lancet; 2017 Jul; 390(10093):490-499. PubMed ID: 28622955
[TBL] [Abstract][Full Text] [Related]
8. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials.
Rothwell PM; Fowkes FG; Belch JF; Ogawa H; Warlow CP; Meade TW
Lancet; 2011 Jan; 377(9759):31-41. PubMed ID: 21144578
[TBL] [Abstract][Full Text] [Related]
9. Dipyridamole for preventing stroke and other vascular events in patients with vascular disease.
De Schryver EL; Algra A; van Gijn J
Cochrane Database Syst Rev; 2003; (1):CD001820. PubMed ID: 12535415
[TBL] [Abstract][Full Text] [Related]
10. Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials.
Berger JS; Roncaglioni MC; Avanzini F; Pangrazzi I; Tognoni G; Brown DL
JAMA; 2006 Jan; 295(3):306-13. PubMed ID: 16418466
[TBL] [Abstract][Full Text] [Related]
11. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. International Stroke Trial Collaborative Group.
Lancet; 1997 May; 349(9065):1569-81. PubMed ID: 9174558
[TBL] [Abstract][Full Text] [Related]
12. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials.
Rothwell PM; Wilson M; Elwin CE; Norrving B; Algra A; Warlow CP; Meade TW
Lancet; 2010 Nov; 376(9754):1741-50. PubMed ID: 20970847
[TBL] [Abstract][Full Text] [Related]
13. Aspirin in primary prevention of cardiovascular disease and cancer: a systematic review of the balance of evidence from reviews of randomized trials.
Sutcliffe P; Connock M; Gurung T; Freeman K; Johnson S; Ngianga-Bakwin K; Grove A; Gurung B; Morrow S; Stranges S; Clarke A
PLoS One; 2013; 8(12):e81970. PubMed ID: 24339983
[TBL] [Abstract][Full Text] [Related]
14. Update on aspirin in the treatment and prevention of cardiovascular disease.
Hennekens CH
Am J Manag Care; 2002 Dec; 8(22 Suppl):S691-700. PubMed ID: 12512736
[TBL] [Abstract][Full Text] [Related]
15. Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus.
; Bowman L; Mafham M; Wallendszus K; Stevens W; Buck G; Barton J; Murphy K; Aung T; Haynes R; Cox J; Murawska A; Young A; Lay M; Chen F; Sammons E; Waters E; Adler A; Bodansky J; Farmer A; McPherson R; Neil A; Simpson D; Peto R; Baigent C; Collins R; Parish S; Armitage J
N Engl J Med; 2018 Oct; 379(16):1529-1539. PubMed ID: 30146931
[TBL] [Abstract][Full Text] [Related]
16. Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials.
Sanmuganathan PS; Ghahramani P; Jackson PR; Wallis EJ; Ramsay LE
Heart; 2001 Mar; 85(3):265-71. PubMed ID: 11179262
[TBL] [Abstract][Full Text] [Related]
17. Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: a meta-analysis of randomized trials.
Berger JS; Krantz MJ; Kittelson JM; Hiatt WR
JAMA; 2009 May; 301(18):1909-19. PubMed ID: 19436018
[TBL] [Abstract][Full Text] [Related]
18. Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis.
van Walraven C; Hart RG; Singer DE; Laupacis A; Connolly S; Petersen P; Koudstaal PJ; Chang Y; Hellemons B
JAMA; 2002 Nov; 288(19):2441-8. PubMed ID: 12435257
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
